Broncus Holding (HKSE:02216) Notes Receivable: HK$0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02216 Broncus Holding Corp HKSE:02216
43 GF Score
Price HK$0.66
GF Value HK$0.15
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Broncus Holding Notes Receivable?

Broncus Holding HKSE:02216 +1.55% 43 Notes Receivable is HK$0.00 Mil as of Jun. 2026. GuruFocus rates HKSE:02216 with a GF Score™ of 43/100 and a GF Value™ of HK$0.15 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Broncus Holding's Notes Receivable for the quarter that ended in Jun. 2026 was HK$0.00 Mil.

Broncus Holding Notes Receivable Related Terms

Broncus Holding Notes Receivable Historical Data

* Premium members only.

The historical data trend for Broncus Holding's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Broncus Holding Notes Receivable Chart

Broncus Holding Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Broncus Holding Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
HKSE:02216
43GF Score
Broncus Holding Corp HKSE:02216
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Broncus Holding Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of HK$0.00 Mil mean?
Broncus Holding (HKSE:02216) has a Notes Receivable of HK$0.00 Mil as of Jun. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Broncus Holding and its competitors.
Is Broncus Holding's Notes Receivable too high?
Broncus Holding's current Notes Receivable is HK$0.00 Mil. Overall, Broncus Holding has a GF Score™ of 43/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Broncus Holding's Notes Receivable compare to ABT and SYK?
Broncus Holding's Notes Receivable of HK$0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Medical Devices & Instruments company?
A good Notes Receivable depends on the Medical Devices & Instruments industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Broncus Holding and its competitors. Broncus Holding's current Notes Receivable is HK$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Broncus Holding stock overvalued right now?
Based on GuruFocus' analysis, Broncus Holding (HKSE:02216) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.15, compared to a current price of HK$0.66 — trading 336.7% above its estimated fair value. The current Notes Receivable is HK$0.00 Mil. Broncus Holding's overall GF Score™ is 43/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Broncus Holding (HKSE:02216), the current Notes Receivable is HK$0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Broncus Holding (HKSE:02216) Overvalued in 2026?

Based on GuruFocus' analysis, Broncus Holding stock appears to be overvalued. The current stock price of HK$0.66 is trading 336.7% above its estimated GF Value™ of HK$0.15. GuruFocus considers Broncus Holding to be Significantly Overvalued.

Key valuation signals for HKSE:02216:

  • Notes Receivable: HK$0.00 Mil
  • GF Value™: HK$0.15 vs. price of HK$0.66 (336.7% above fair value)
  • GF Score™: 43/100 with 7 warning signs

No single metric tells the full story. See the HKSE:02216 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Broncus Holding Business Description

Address No. 88 Jiangling Road, Xixing Street, Room 801, 8th Floor, Building 8, Binjiang District, Hangzhou, CHN
Broncus Holding Corp is focused on provision of interventional treatment of Chronic Obstructive Pulmonary Disease and lung cancer. It engages in the field of Interventional Pulmonology, providing solutions for lung diseases in China and globally. Its products portfolio includes the InterVapor Thermal Vapor Treatment System the only implantable medical device to treat COPD; BroncAblate Radiofrequency Ablation System the transbronchial interventional treatment product for lung cancer; Targeted Lung Denervation Radiofrequency Ablation System the self-developed targeted radiofrequency ablation system in China to reduce the risk of acute exacerbation of COPD. Geographically, the company operates in Chinese Mainland; European Union; and Other Regions.
43GF Score

Get the complete analysis for HKSE:02216

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$0.66
Price
HK$0.15
GF Value